Michal Dranitzki Elhalel
Corporate Officer/Principal presso Hadassah University Hospital
Profilo
Michal Dranitzki Elhalel is currently the Head of the Nephrology Department at Hadassah University Hospital.
Previously, she worked as the Chief Scientist at KAHR Medical Ltd.
She obtained a doctorate degree from The Hebrew University Hadassah Medical School.
Posizioni attive di Michal Dranitzki Elhalel
| Società | Posizione | Inizio |
|---|---|---|
Hadassah University Hospital
 Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Corporate Officer/Principal | - |
Precedenti posizioni note di Michal Dranitzki Elhalel
| Società | Posizione | Fine |
|---|---|---|
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Michal Dranitzki Elhalel
| The Hebrew University Hadassah Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Hadassah University Hospital
Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Health Services |
- Borsa valori
- Insiders
- Michal Dranitzki Elhalel
